Amivantamab Plus Lazertinib Vs Osimertinib in Firstline EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
S. Gadgeel,B. C. Cho,S. Lu,E. Felip,H. Hayashi,A. I. Spira,B. Besse, M. Thomas,S. Owen,Y. J. Kim,S. -H. Lee,J. Mourao Dias,Y. -G. Lee, Y. Zhao, Y. Fang,N. Girard, Z. Liu,P. Sun, S. C. Sousa Oliveira, H. Shen,L. Paz-Ares, S. Matsumoto, H. Tanaka, A. R. Ahmad, T. Andabekov,P. Sunpaweravong, O. Ozyilkan,J. C. -H. Yang,M. Gottfried, O. Hernandez,M. Kimmich,D. Cortinovis, D. L. Kaen, L. V. Garcia Montes,S. Popat, T. Newsom-Davis,J. Xie,T. Sun,E. Fennema, M. Daksh, M. Ennis, S. Sethi,J. M. Bauml,D. Nguyen JOURNAL OF THORACIC ONCOLOGY（2024）
Key words
amivantamab,lazertinib,NSCLC mutations
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper